Skip to content
JULY 16, 2025
Commercial potential
of Kodiak’s 3 late-phase clinical assets
•
BLA facing
data in 2026
•
New
KSI-101 clinical data
Commercial potential
of Kodiak’s 3 late-phase clinical assets
BLA facing
data in 2026
New
KSI-101 clinical data
Register for Kodiak’s
2025 Investor R&D Day →
Toggle navigation
Our Company
Our Science
ABCD Platform
Science Of Durability
Scientific Presentations
Focus Areas
Diabetic Eye Disease
Retinal Vein Occlusion
Wet Age Related Macular Degeneration
Our Pipeline
TARCOCIMAB TEDROMER
KSI-501
KSI-101
Our Culture
Join the Team
Investors & Media
Overview
Press Releases
ESG Report
Events and Presentations
Stock Information
Analyst Coverage
SEC Filings
Corporate Governance
Investor Resources
Our Company
Our Science
ABCD Platform
Science Of Durability
Scientific Presentations
Focus Areas
Diabetic Eye Disease
Retinal Vein Occlusion
Wet Age Related Macular Degeneration
Our Pipeline
TARCOCIMAB TEDROMER
KSI-501
KSI-101
Our Culture
Join the Team
Investors & Media
Overview
Press Releases
ESG Report
Events and Presentations
Stock Information
Analyst Coverage
SEC Filings
Corporate Governance
Investor Resources
KSI-501: A Novel Bispecific Antibody Biopolymer Conjugate Targeting IL-6 and VEGF
July 1, 2024
By
X
1250 Page Mill Road
Palo Alto, CA 94304
United States of America